
|Articles|July 28, 2015
Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
T-DXd/Pertuzumab Combo Earns FDA Approval in Advanced HER2+ Breast Cancer
2
FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC
3
Pembrolizumab Plus RT Ups T-Cell Infiltration in Early Breast Cancer
4
Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma
5
















































































